Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

Rhea-AI Summary

Graviton Bioscience (NASDAQ:MGTX) will present selective ROCK2 obesity data at the 8th Annual Evercore HealthCONx Conference on December 2, 2025 at 8:45 AM ET. CEO Samuel Waksal will lead a fireside chat covering Graviton's obesity program and its selective ROCK2 inhibitor, GV101.

Key points to be discussed include:

• Target biology: ROCK2 roles in fibrosis, inflammation, cytoskeletal mechanics, and adipose tissue.
• Preclinical efficacy: GV101 reduced lipid droplets in mouse and human adipocytes and produced weight loss in rodent models with lean mass preservation.
• Clinical significance: GV101 appears to sustain fat loss while preserving muscle.

The presentation will be webcast and open to media, investors, and the public.

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, among other therapeutic indications, today announced that Samuel Waksal, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference. Details of the fireside chat are as follows:

• Tuesday, December 2, 2025 at 8:45am Eastern Time

The fireside chat will provide an overview of Graviton's obesity research program and selective ROCK2 inhibitor development, highlighting:

• Target Biology . ROCK2 (Rho-associated coiled-coil containing protein kinase 2) is involved in fibrosis, inflammation, and cytoskeletal mechanics, as well as being present in adipose tissue; Graviton's GV101 is a highly selective ROCK2 inhibitor.
  
  
• Preclinical Efficacy . In rodent obesity models, GV101 reduces lipid droplets both in mouse and human adipocytes. Graviton's ROCK2 inhibitors decrease weight similarly to GLP-1 RAs with relative lean mass preservation.
  
  
• Clinical Significance . GV101 appears to lead to sustained fat loss while preserving muscle, thus promoting healthier weight loss.

The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors, and the general public.

About Graviton Bioscience
Graviton Bioscience Corporation is a clinical stage drug discovery and development company, dedicated to engineering and developing best-in-class therapeutics for treating metabolic, CNS, inflammatory, fibrotic, and multiple other disease indications including where ROCK2 plays a pivotal role in pathology. Graviton's first drug candidate, GV101, is in clinical studies, with additional assets advancing through the preclinical pipeline. Leading the company is Dr. Samuel Waksal, the founder and former Chairman and CEO of Kadmon Pharmaceuticals (acquired by Sanofi). Dr. Waksal is also the founder and former CEO of ImClone Systems (acquired by Eli Lilly) and a founder of MeiraGTx (NASDAQ: MGTX).

Forward-Looking Statements
This press release contains forward-looking statements regarding Graviton's development plans, regulatory strategy, and potential future clinical applications for its selective ROCK2 inhibitors. Such statements are subject to risks and uncertainties, including, but not limited to, biological, clinical, regulatory, financial, and operational risks. Actual results may differ materially.

Graviton Bioscience Contact:

Melanie Glickman

Senior Associate, Operations Strategy

Melanie.Glickman@gravitoncorp.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/graviton-bioscience-to-present-selective-rock2-obesity-data-at-8th-annual-evercore-healthconx-conference-302622251.html

SOURCE Graviton Bioscience

FAQ

When will Graviton Bioscience (MGTX) present at Evercore HealthCONx?

The fireside chat is scheduled for December 2, 2025 at 8:45 AM ET.

What will Graviton discuss about GV101 at the MGTX presentation?

The company will discuss GV101's selective ROCK2 biology, preclinical obesity efficacy, and potential clinical significance.

Does Graviton (MGTX) report clinical results for GV101 at the conference?

The presentation will overview obesity research and preclinical data; no new clinical trial readouts are specified in the announcement.

How did GV101 perform in preclinical obesity models according to Graviton's announcement?

GV101 reduced lipid droplets in mouse and human adipocytes and produced weight loss in rodent models with relative lean mass preservation.

Will the Graviton (MGTX) fireside chat be available to investors online?

Yes, the webcast will be broadcast over the internet and available to media, investors, and the general public.

What aspects of ROCK2 will Graviton highlight for its obesity program?

Graviton will highlight ROCK2's role in fibrosis, inflammation, cytoskeletal mechanics, and its presence in adipose tissue.